Gynecology and Obstetrics Research · Vol. 2, No. 5 · 2015 · pp. 96–98 · e-ISSN 2377-1542

Pregnancy in Takayasu Arteritis Patients Exposed to Anti-Tumour Necrosis Factor (Anti-TNF)-α Therapy

Valentina Canti, Elena Baldissera, Susanna Rosa, Giuseppe A. Ramirez, Isadora Vaglio Tessitore, Maria Grazia Sabbadini, Maria Teresa Castiglioni, Patrizia Rovere-Querini

DOI: https://doi.org/10.17140/goroj-2-122 · Published 2015-12-04 · Licence: https://creativecommons.org/licenses/by/4.0 · © 2015 The Author(s)

Also available as PDF (figures and tables appear in the PDF).

Abstract

First patient, a 35 year old woman with a diagnosis of ulcerative colitis since childhood, was diagnosed with TA in 2009. She had an uncomplicated pregnancy in 2004. When she planned a second pregnancy, she was receiving IFX7 mg/kg every-six-weeks plus chronic therapy.

Acknowledgements

left carotid arteries, occlusion of the right carotid artery, bilateral occlusion of the subclavian artery and thickening of the aortic- The work of the authors is supported by the Italian Ministry of arch. PET-scan confirmed increased uptake of contrast media in Health (Ricerca Finalizzata 2009, 2011).

the aortic-arch and brachiocephalic, left subclavian and left axillary arteries. At conception she had type IIa disease (involve-

Consent

ment of the ascending portion of aorta and the aortic arch).2 AZA was discontinued in the first 12 wg and IFX was stopped at 28 The patients have signed a generic informed consent.

wg; aspirin 100 mg daily was administered until 35 wg. Blood pressure remained consistently normal. At 30 wg Erythrocyte

References

  1. TombettiEDi ChioMSartorelliS. Systemic pencomplained of carotidodynia. Prednisone was increased (15 traxin-3 levels reflect vascular enhancement and progression mg) and then tapered. Echocardiography at 12 and 28 wg and in Takayasu arteritis. Arthritis Res Ther. 2014; 16: 479. doi: carotid ultrasonography at 24 wg were consistent with TA sta- 10.1186/s13075-014-0479-z bility. Ultrasonography repeatedly showed normal fetal growth, umbilical and placental flow. At 38 wg she delivered a healthy10.1186/s13075-014-0479-z https://doi.org/10.1186/s13075-014-0479-z
  2. HataANodaMMoriwakiRNumanoF. Angiographic findchild. TADS score was stable during pregnancy. Histopathoings of Takayasu arteritis: new classification. Int J Cardiol. 1996; logical analysis of the placenta revealed no arteritic feature. 54 Suppl: S155-S163. doi: 10.1016/0167-5273(96)02651-4 Breastfeeding was allowed. One month after delivery the patient discontinued the therapy and was lost to clinical follow-up for10.1016/0167-5273(96)02651-4 https://doi.org/10.1016/0167-5273(96)02651-4
  3. MasonJC. Takayasu arteritis-advances in diagnosis and mantwo months. She developed low-grade fever, carotidodynia, upagement. Nat Rev Rheumatol. 2010; 6: 406-415. doi: 10.1038/ per and lower limbs claudication in addition to high ESR and nrrheum.2010.82 CRP. IFX was re-introduced with immediate benefit. MRA three months after delivery was consistent with disease stability
  4. SivakumarRMisraRDandaDMahendranathKMBaconPA. Development of an index to assess disease-related damage TA mainly affects women during child-bearing years.2 in takayasu arteritis and use in outcome of vascular interventions. Rheumatology. 2012; 51: 3140-3184
  5. TanakaHTanakaKKamiyaCIwanagaNYoshimatsuJ. Analysis of pregnancies in women with Takayasu arteritis: complication of takayasu arteritis involving obstetric or cardiovascular events. J Obstet Gynaecol Res. 2014; 40: 2031-2036. doi: 10.1111/jog.1244310.1111/jog.12443 https://doi.org/10.1111/jog.12443
  6. RamirezGAMaugeriNSabbadiniMGRovere-QueriniPManfrediAA. Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum. Clin ExpImmunol. 2014; 175: 150-166. doi: 10.1111/cei.1222310.1111/cei.12223 https://doi.org/10.1111/cei.12223
  7. ChaparroMGisbertJP. How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease? Expert Opin Drug Saf. 2014; 13(12): 1749-1762. doi: 10.1517/14740338.2014.95948910.1517/14740338.2014.959489 https://doi.org/10.1517/14740338.2014.959489
  8. CalligaroAHoxhaARuffattiAPunziL. Are biological drugs safe in pregnancy? Reumatismo. 2015; 66(4): 304-317. doi: 10.4081/reumatismo.2014.79810.4081/reumatismo.2014.798 https://doi.org/10.4081/reumatismo.2014.798